Raymond James Lowers DRI Healthcare Trust (TSE:DHT.UN) Price Target to C$22.00

DRI Healthcare Trust (TSE:DHT.UN) had its target price lowered by Raymond James from C$23.00 to C$22.00 in a note issued to investors on Wednesday,BayStreet.CA reports. Raymond James’ target price points to a potential upside of 68.84% from the company’s current price.

A number of other brokerages have also weighed in on DHT.UN. Truist Financial cut their target price on shares of DRI Healthcare Trust from C$17.00 to C$14.00 in a research note on Thursday, July 25th. Scotiabank lifted their target price on shares of DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of C$18.00.

DRI Healthcare Trust Trading Up 37.9 %

TSE:DHT.UN opened at C$13.03 on Wednesday. The company has a fifty day moving average of C$13.30 and a 200 day moving average of C$13.63. DRI Healthcare Trust has a 52 week low of C$10.39 and a 52 week high of C$17.43.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.